CD22 and lymphoma: Whereas, the abilities of glycoengineered of NK cells to bind and kill CD22 + lymphoma cells were significantly improved when cells were modified with 9-O modified sialic acid-based CD22 ligands (Haso et al., 2013; Ereño-Orbea et al., 2017).